AMGEN INC

Amgen’s performance at the Morgan Stanley Global Healthcare Conference reveals a blend of trial setbacks and bold innovation—investors see cautious optimism in its biotech growth strategy.

Amgen shares drop 5% as Lp(a) therapy doubts hit investor confidence, amid three‑fold negative news and political scrutiny.

Amgen’s 8.6 % stock surge after beating earnings shows promise—but regulators, biosimilar competition and Tavneos suspension raise key risks that investors will watch at the upcoming Wells Fargo Healthcare Conference.

Amgen’s Repatha shows first‑in‑class mortality benefit in primary prevention, while the UK’s Tavneos suspension highlights rising regulatory scrutiny in the biotech sector.

Amgen insider trades revealed: a senior executive’s Form 4 filing shows buying, selling, and convertible rights exercised on Amgen stock—transparent insight for investors.

Amgen’s Q2 earnings soar: net income climbs $2.375 B, Repatha sales jump 37% and full‑year guidance is raised—investors rally amid strong biotech growth.

Amgen raises its dividend and expands Repatha’s indication to prevent first heart attacks, boosting investor confidence and opening new European markets.

Amgen shares slip 2% on July 9, 2026 while Nasdaq climbs, amid FDA approval of a new oncology biosimilar that could reshape the biotech race.

Amgen’s 3.55% rally on July 2 shows biotech resilience: strong earnings, a growing therapeutic pipeline, and a 52‑week high within reach—investors eye continued upside.

Amgen’s latest investor outreach, market positioning and collaborative drug trials highlight its biotech leadership and AI‑driven innovation potential.